Kyntra Bio (KYNB) versus Its Peers Critical Survey

Kyntra Bio (NASDAQ:KYNB) is one of 456 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Kyntra Bio to related businesses based on the strength of its institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Profitability

This table compares Kyntra Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,662.14%	-363.93%	-42.95%

Analyst Recommendations

This is a breakdown of recent ratings for Kyntra Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	0	0	1.50
Kyntra Bio Competitors	4894	9963	15989	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 63.91%. Given Kyntra Bio’s peers stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio has less favorable growth aspects than its peers.

Insider & Institutional Ownership

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 2.0% of Kyntra Bio shares are owned by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Kyntra Bio and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$29.62 million	-$47.58 million	0.14
Kyntra Bio Competitors	$432.12 million	-$67.78 million	-10.65

Kyntra Bio’s peers have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Kyntra Bio has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Kyntra Bio’s peers have a beta of 5.48, meaning that their average stock price is 448% more volatile than the S&P 500.

Summary

Kyntra Bio peers beat Kyntra Bio on 7 of the 13 factors compared.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.